Polycomb protein SUZ12 Antibodies

Polycomb protein SUZ12 (SUZ12)

Polycomb group (PcG) protein. Component of the PRC2/EED- EZH2 complex, which methylates'Lys-9' (H3K9me) and'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene.

The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.

Gene Information

Human
Gene Name:	SUZ12
Uniprot:	Q15022
Entrez:	23512

Family

Belongs to:
VEFS (VRN2-EMF2-FIS2-SU(Z)12) family

Alternative Names

ChET 9 protein; CHET9; CHET9polycomb protein SUZ12; Chromatin precipitated E2F target 9 protein; JJAZ1; JJAZ1Joined to JAZF1 protein; KIAA0160Suppressor of zeste 12 protein homolog; suppressor of zeste 12 homolog (Drosophila); SUZ12

Molecular Weight

Mass (kDA):
83.055 kDA

Genomic Context

Human
Location:	17q11.2
Sequence:	17; NC_000017.11 (31937007..32001040)

Tissue Specificity

Overexpressed in breast and colon cancer.

Subcellular Localizations

Nucleus.

Diseases

• Malignant Neoplasms
• Neoplasms
• Leukemia
• Neurofibromatosis 1
• Malignant Neoplasm Of Breast
• Cell Transformation, Neoplastic
• Carcinoma
• Myeloid Leukemia
• Malignant Paraganglionic Neoplasm
• Neoplasm Metastasis
• Lymphoma
• Leukemia, Myelocytic, Acute
• Mammary Neoplasms

• Endometrial Polyp
• Malignant Neoplasm Of Prostate
• Myeloproliferative Disease
• Prostatic Neoplasms
• Cell Invasion
• Hyperplasia
• Neurofibromatoses

Interacting Proteins

• EED
• EZH2
• HDAC3
• HLX

Pathways

• Methylation
• Cell Differentiation
• Gene Silencing
• Histone Methylation
• Cell Proliferation
• Dna Methylation
• Histone Modification
• Pathogenesis
• Stem Cell Differentiation
• Chromatin Remodeling
• Localization
• Cell Growth
• Dna Hypermethylation

• Demethylation
• Oncogenesis
• Fertilization
• Cell Cycle
• Mitosis
• Rna Interference
• Regulation Of Histone Methylation

PTMs

• Methylation
• Acetylation
• Demethylation

• Ubiquitination
• Cleavage
• Sumoylation

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SUZ12

Best Uses Of The SUZ12 Marker

Scientists can submit results to SUZ12 for publications. This product is applicable to scientists worldwide. The results submitted by scientists may be used in the creation of new products or for product credits. Boster scientists may also submit their results for special samples, species, or applications to gain product credits. Boster Bio provides this product free of charge to all scientists.

HNSCC could use SUZ12 for a putative oncogene

SUZ12 may serve as a potential therapeutic target in the treatment of HNSCC. SUZ12 has been shown to suppress growth and metastasis and to decrease expression of E2F1, ROCK1, and ROBO1. SUZ12 silencing also inhibited tumor cell invasion and migration. SUZ12 knockdown also significantly reduced expression of Rho-associated protein kinase-1.

SUZ12 levels are decreased in HNSCC tissues. It is believed to target CCR7 and inhibit the progression. Fadhil and coworkers have also shown that salivary let-7a-5p expression correlates with clinical outcome, lymphoma stage, and cancer stage.

SUZ12 could be a potential oncogene in HNSCC. SUZ12 has also been linked to aberrant Bmi1 transcription, which is a critical regulator for HNSCC. Abnormal Bmi1 expression may serve as a molecular event driving the occurrence of HNSCC. However, we still don't have a complete understanding of HNSCC tumorigenesis. To understand the molecular events driving tumorigenesis, it is crucial to identify new therapeutic targets and biomarkers.

CCDC43 was cotransfected into GC cell lines. The expression of HMGA1 was upregulated in BGC-823 cells and decreased in AGS cells. HGMA1 directly targets the transcription of SUZ12 (and CCDC43)

Studies on the suppressor zeste-12, (SUZ12), protein have previously shown that it is a potential HNSCC-oncogene. The suppressor of zeste-12 protein is a core component of Polycomb repressive complex 2 and is implicated in transcriptional silencing and generates di and tri-methylation of lysine 27 on histone H3. Although SUZ12 has been shown to be important in several types of tumorigenesis it is not yet clear what its function in HNSCC.

The mutation pattern of SUZ12 has been identified by comprehensive data mining and interrogation of publicly available databases. PTC-209, a potent inhibitor against Bmi1, has been developed by the researchers. It inhibits Bmi1. PTC-209 was shown to significantly reduce Bmi1 expression in HNSCC cells from two different lines. The inhibitor's effects on HNSCC cell phenotypes were also evaluated in a xenograft model.